From January 1, 2023 to March 31, 2023, the company has repurchased 87,694 shares, representing 1.06% for $0.3 million. With this, the company has completed the repurchase of 225,220 shares, representing 2.7% for $0.96 million under the buyback announced on August 16, 2022.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.39 USD | -4.02% |
|
-3.63% | -24.84% |
Jun. 04 | Lumos Pharma, Inc. Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024 | CI |
May. 15 | Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.84% | 19.4M | |
+37.28% | 53.67B | |
+33.79% | 38.86B | |
-8.32% | 38.76B | |
-8.98% | 27.27B | |
+11.12% | 25.91B | |
-15.24% | 20.29B | |
+31.05% | 12.78B | |
+27.70% | 12.18B | |
-2.20% | 11.96B |
- Stock Market
- Equities
- LUMO Stock
- News Lumos Pharma, Inc.
- Tranche Update on Lumos Pharma, Inc.'s Equity Buyback Plan announced on August 16, 2022.